2.42
+1.68%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Chaoju Eye Care Holdings
Its shares trade on HKEX under the ticker 2219.HK. It has been listed since 7 July 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.59bn and net income of CN¥213.9m. At that date it held total assets of CN¥3.52bn and shareholders' equity of CN¥2.80bn.
Chaoju Eye Care Holdings Ltd. engages in the provision of ophthalmic medical services. The company is headquartered in Beijing, Beijing. The company went IPO on 2021-07-07. The firm operates its businesses through two segments. The Consumer Ophthalmic Services segment provides refractive correction (including presbyopia correction), myopia control and provides optical products and services. The Basic Ophthalmic Services segment provides treatments of a wide range of common eye diseases, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases and pediatric eye diseases, which may be covered by public health insurance programs. The firm mainly conducts its businesses in the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 7 Jul 2021
- Employees
- 2,389
- Website
- chaojueye.com ↗
Leadership
Pay as last reported
- Mr. Bozhou ZhangExecutive Chairman of the Board, Chief Executive Officer, since 2020CN¥1.4m
- Mr. Weichao WangChief Financial Officer
- Mr. Hongyan LiuChief Operating Officer
- Mr. Guangdi ZhangExecutive Director, since 2020CN¥730,000
- Mr. Junfeng ZhangExecutive Director, since 2020CN¥371,000
- Ms. Xiaoli ZhangExecutive Director, since 2020CN¥1.5m
- Ms. Yajun YangChief Medical Officer
- Mr. Ching Kit ChengJoint Company Secretary
- Ms. Chun XieJoint Company Secretary, Chief Strategy Officer
- Mr. Mao ChenNon-Executive Director
- Mr. Zhen LiNon-Executive Director
- Ms. Li ZhangNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Beijing with 2,389 employees
- Operates through two segments: Consumer Ophthalmic Services and Basic Ophthalmic Services
- Provides refractive correction, myopia control, and optical products and services
Weaknesses
- Relies solely on the domestic market for business operations
- IPO occurred in 2021, indicating a relatively new public company
- No mention of international presence or diversification
Opportunities
- Expansion into international markets for growth
- Potential to increase market share in ophthalmic medical services
- Growth opportunities in public health insurance-covered treatments
Threats
- Dependence on domestic market may limit growth potential
- Competition in the ophthalmic medical services sector
- Regulatory changes affecting public health insurance programs
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.